Research programme: GTP-binding protein inhibitors - Ipsen

Drug Profile

Research programme: GTP-binding protein inhibitors - Ipsen

Alternative Names: BIM-46174; BIM-46187

Latest Information Update: 10 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ipsen
  • Developer Institut Henri Beaufour-Ipsen; Ipsen; Oncodesign Biotechnology
  • Class Imidazoles; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; GTP-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Cancer pain

Most Recent Events

  • 13 Dec 2010 Preclinical development is ongoing in France
  • 10 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section
  • 14 Aug 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top